We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS Secretary Alex Azar offered more details on Monday of a plan that could expand Medicare’s ability to negotiate prices, implicitly responding to claims that the administration’s new drug pricing blueprint is too easy on drugmakers. Read More
Green was alleged to have acquired shares in Southwest for a nominal sum in exchange for a guaranteed “dividend” worth about $5,000 per month, as long as she referred a certain amount of urine drug screens. Read More
Sponsors of pediatric HIV drugs should conduct bioequivalence studies in adults and enroll clinical trial subjects in cohorts based on weight rather than age, according to new FDA draft guidance. Read More
In a long-anticipated speech on drug pricing, President Trump announced reforms that “will bring soaring drug prices back down to earth,” but he cited few specifics and appeared to back off from a campaign promise to fight for Medicare to directly negotiate prescription prices. Read More
“[We] need to ensure that our ports are adequately staffed and equipped to deal with this problem—and right now that’s simply not the case,” said Sen. Claire McCaskill (D-Mo.). Read More
U.S. officials seized more than 12 tons of illicit opioids at ports of entry between 2013 and 2017, according to a new report that bolsters FDA Commissioner Scott Gottlieb’s call for more international mail facility staff to stem the addiction epidemic. Read More